NPC(SH:600713)2023-10-30 16:00Financial Performance - The company's operating revenue for Q3 2023 was CNY 13,203,658,118.16, a decrease of 2.16% compared to the same period last year[4] - The net profit attributable to shareholders was CNY 131,653,503.45, down 3.92% year-on-year[4] - The basic earnings per share for the quarter was CNY 0.10, reflecting a decline of 7.27% compared to the previous year[4] - Total operating revenue for the first three quarters of 2023 reached ¥40.55 billion, an increase of 8.3% compared to ¥37.44 billion in the same period of 2022[35] - Net profit for the first three quarters of 2023 was ¥532.96 million, a decrease of 4.1% from ¥555.61 million in the same period of 2022[36] - The basic earnings per share for the first three quarters of 2023 was ¥0.34, down from ¥0.38 in the same period of 2022[37] Assets and Liabilities - Total assets at the end of the reporting period reached CNY 33,202,829,130.69, an increase of 4.90% from the end of the previous year[4] - The total assets as of September 30, 2023, amounted to ¥20,655,438,149.64, compared to ¥17,887,960,122.52 at the end of 2022, indicating an increase of 15.5%[43] - The total liabilities of the company as of the end of the third quarter of 2023 amounted to ¥26.14 billion, an increase from ¥24.96 billion at the end of 2022[36] - The total liabilities increased to ¥15,425,338,619.69 as of September 30, 2023, from ¥12,855,143,912.17 at the end of 2022, marking a rise of 20.5%[43] Cash Flow - The cash flow from operating activities showed a significant decrease due to an increase in accounts receivable[7] - The company's cash flow from operating activities showed a net outflow of ¥4.48 billion in the first three quarters of 2023, compared to a net outflow of ¥3.21 billion in 2022[38] - The cash inflow from operating activities totaled ¥40.96 billion in the first three quarters of 2023, compared to ¥34.92 billion in 2022, indicating a growth of 17.5%[38] - The net cash flow from operating activities was negative at approximately -¥821.53 million, worsening from -¥687.11 million year-on-year[47] Shareholder Information - The company has a total of 61,552 ordinary shareholders as of the reporting period[9] - The company reported a total equity attributable to shareholders of CNY 6,291,889,649.71, up 4.87% from the previous year[4] - The company's total equity reached ¥7.07 billion by the end of the third quarter of 2023, compared to ¥6.69 billion at the end of 2022, reflecting a growth of 5.6%[36] - The total equity of the company as of September 30, 2023, was ¥5,230,099,529.95, up from ¥5,032,816,210.35 at the end of 2022, indicating a growth of 3.93%[43] Investments and Projects - The company plans to raise up to CNY 1,081.49 million through convertible bonds, with key projects including digital transformation and logistics center expansion[11] - The company has approved a total R&D budget of CNY 3,062 million for multiple projects, with Nanjing Pharmaceutical responsible for CNY 2,725.60 million[25] - The company is investing up to CNY 149.63 million in the construction of the Nanjing Pharmaceutical Central Logistics Integration Project[28] - Nanjing Pharmaceutical has completed the acquisition of 100% equity in Hubei Kaipute Pharmaceutical Co., Ltd. for CNY 0.32 million, with a subsequent capital increase of CNY 6.90 million[26] Research and Development - Research and development expenses increased to ¥28.51 million in 2023 from ¥21.89 million in 2022, marking a rise of 30.3%[36] - The company's R&D expenses for the first three quarters of 2023 were ¥6,771,698.11, slightly higher than ¥6,386,980.48 in the same period of 2022[44] Market Strategy - The company plans to continue expanding its market presence and investing in new technologies and products to drive future growth[49] - The company has implemented new accounting standards starting in 2023, which may affect the financial reporting and analysis going forward[48]